Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Non-Current Assets (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Other Non-Current Assets for 9 consecutive years, with $25.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets fell 5.21% to $25.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $25.1 million, a 5.21% decrease, with the full-year FY2024 number at $24.7 million, up 36.37% from a year prior.
  • Other Non-Current Assets was $25.1 million for Q3 2025 at Denali Therapeutics, up from $23.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $50.6 million in Q2 2024 to a low of $3.6 million in Q2 2021.
  • A 5-year average of $19.0 million and a median of $15.2 million in 2022 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: surged 382.17% in 2021, then plummeted 54.58% in 2025.
  • Denali Therapeutics' Other Non-Current Assets stood at $11.9 million in 2021, then rose by 12.87% to $13.4 million in 2022, then soared by 35.41% to $18.1 million in 2023, then surged by 36.37% to $24.7 million in 2024, then grew by 1.48% to $25.1 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Other Non-Current Assets are $25.1 million (Q3 2025), $23.0 million (Q2 2025), and $26.9 million (Q1 2025).